Impact of Combination Antibiogram and Related Education on Inpatient Fluoroquinolone Prescribing Patterns for Patients With Health Care-Associated Pneumonia

The Annals of Pharmacotherapy
Baoqi LiangLisa M Blanchette

Abstract

Previous studies have shown that development of a unit-specific combination antibiogram improves optimal selection of empiric therapy for Gram-negative infections, yet no published data exist regarding the role of the combination antibiogram as an antimicrobial stewardship program tool for disease-specific prescribing. To evaluate the utility of a combination antibiogram to guide antibiotic prescribing for patients with health care-associated pneumonia (HCAP). This was a retrospective preprovider and postprovider education intervention study aimed to evaluate fluoroquinolone (FQ) use in patients with HCAP. Data were collected retrospectively to evaluate antibiotic prescribing patterns and patient outcomes. A total of 87 patients were eligible for study inclusion. The primary end point, FQ days of therapy (DOT) was decreased by 2.3 days (P < 0.001). The secondary end point included FQ DOT per 1000 patient-days in patients with discharge diagnosis-related group of pneumonia and was decreased by 83.5 days (P = 0.08); double coverage reduced by 13% postintervention (P = 0.22); mean days of double coverage decreased by 2.1 days (P < 0.001), and length of stay was shortened by 2.1 days (P = 0.22). Clinical success was achieved more o...Continue Reading

References

Jan 21, 2003·Emerging Infectious Diseases·W Michael Scheld
Feb 18, 2003·JAMA : the Journal of the American Medical Association·Melinda M NeuhauserJohn P Quinn
Feb 27, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Dale N Gerding
Oct 6, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jacques PépinLuc Lanthier
Apr 20, 2006·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Mari MizutaEbbing Lautenbach
Aug 8, 2007·Antimicrobial Agents and Chemotherapy·Scott T MicekMarin H Kollef
Jan 9, 2010·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Jennifer ChristoffStephen G Weber
Jul 17, 2013·American Journal of Respiratory and Critical Care Medicine·Yuichiro ShindoYoshinori Hasegawa
Sep 4, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Takaya MaruyamaMichael S Niederman
Nov 26, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·James D ChalmersSantiago Ewig
Jun 25, 2014·Antimicrobial Agents and Chemotherapy·Alan E GrossAndre C Kalil
Jul 15, 2015·The New England Journal of Medicine·Seema JainUNKNOWN CDC EPIC Study Team

❮ Previous
Next ❯

Citations

May 4, 2017·Workplace Health & Safety·Sylvia R Judd
May 12, 2018·BMC Pregnancy and Childbirth·Christina PrindsMette Bliddal
Nov 18, 2017·International Journal of Clinical Pharmacy·Samantha S WangWilliam R Judd
Jul 6, 2021·JAC-antimicrobial Resistance·William R TruongJason Yamaki

❮ Previous
Next ❯

Methods Mentioned

BETA
X-ray

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America
Jason M PogueDaryl D DePestel
Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America
Yanina DubrovskayaSapna A Mehta
South Dakota Medicine : the Journal of the South Dakota State Medical Association
Brad R Laible
© 2022 Meta ULC. All rights reserved